Polyrizon启动Nasarix™过敏阻断剂可用性研究项目,推进监管审批进程

美股速递
Jan 22

Polyrizon有限公司在推进其主打产品Nasarix™过敏阻断剂的监管审批道路上迈出了关键一步,正式启动了该产品的可用性研究项目。这一举措旨在评估产品的实际使用体验与性能,为后续向监管机构提交申请收集必要的数据支持。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10